GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Depomed, Inc. (DEPO) [hlAlert]

Rating:
Buy DEPO
up 423.63 %

Depomed, Inc. (DEPO) rated Buy with price target $10 by Auriga

Posted on: Friday,  Sep 30, 2011  8:25 AM ET by Auriga

Auriga rated Buy Depomed, Inc. (NASDAQ: DEPO) on 09/30/2011, when the stock price was $5.50. Since
then, Depomed, Inc. has gained 423.64% as of 01/07/2016's recent price of $28.80.
If you would have followed this Auriga's recommendation on DEPO, you would have gained 423.63% of your investment in 1560 days.

Depomed, Inc. (Depomed) is a specialty pharmaceutical company focused on the development and commercialization of differentiated products that are based on oral drug delivery technologies. Depomed has developed two commercial products: GLUMETZA (metformin hydrochloride extended release tablets), which is a once-daily treatment for adults with type 2 diabetes that it commercializes in the United States with Santarus, Inc. (Santarus). ProQuin XR (ciprofloxacin hydrochloride extended release tablets), which is a once-daily treatment for uncomplicated urinary tract infections that Depomed commercializes in the United States with Watson Pharma (Watson).

Auriga operates full-service institutional equity and fixed income trading desks with state-of-the-art communications technology and trading systems. Through our U.S. corprate parent, Auriga Holdings, LLC we offer a variety of services including whole loan trading and asset management. Through our Spanish parent company, Auriga Securities Sociedad de Valores, S.A., we offer the ability to trade European equity and fixed income products. We connect electronically to buy-side firms; route orders to multiple points of execution and subsequently route to our clearing firm, Pershing, for settlement.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
9/30/2011 8:25 AM Buy
None
5.50 10.00
as of 12/30/2011
1 Week up  3.80 %
1 Month up  6.36 %
3 Months down  -5.81 %
1 YTD down  -5.81 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy